[go: up one dir, main page]

WO2016156920A1 - Procédé de fabrication d'un médicament à base de plantes au moyen d'une enzyme de l'estomac du moustique pour le traitement de virus et du sida - Google Patents

Procédé de fabrication d'un médicament à base de plantes au moyen d'une enzyme de l'estomac du moustique pour le traitement de virus et du sida Download PDF

Info

Publication number
WO2016156920A1
WO2016156920A1 PCT/IB2015/052367 IB2015052367W WO2016156920A1 WO 2016156920 A1 WO2016156920 A1 WO 2016156920A1 IB 2015052367 W IB2015052367 W IB 2015052367W WO 2016156920 A1 WO2016156920 A1 WO 2016156920A1
Authority
WO
WIPO (PCT)
Prior art keywords
aids
mosquito
stomach
enzyme
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/052367
Other languages
English (en)
Inventor
Seyyed Milad ABRISHAMIFAR
Melika YOUSEFI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2016156920A1 publication Critical patent/WO2016156920A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L50/00—Electric propulsion with power supplied within the vehicle
    • B60L50/10—Electric propulsion with power supplied within the vehicle using propulsion power supplied by engine-driven generators, e.g. generators driven by combustion engines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L50/00—Electric propulsion with power supplied within the vehicle
    • B60L50/10—Electric propulsion with power supplied within the vehicle using propulsion power supplied by engine-driven generators, e.g. generators driven by combustion engines
    • B60L50/15—Electric propulsion with power supplied within the vehicle using propulsion power supplied by engine-driven generators, e.g. generators driven by combustion engines with additional electric power supply
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L50/00—Electric propulsion with power supplied within the vehicle
    • B60L50/50—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells
    • B60L50/60—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
    • B60L50/61—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries by batteries charged by engine-driven generators, e.g. series hybrid electric vehicles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L2220/00—Electrical machine types; Structures or applications thereof
    • B60L2220/40—Electrical machine applications
    • B60L2220/44—Wheel Hub motors, i.e. integrated in the wheel hub
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/60—Other road transportation technologies with climate change mitigation effect
    • Y02T10/62—Hybrid vehicles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/60—Other road transportation technologies with climate change mitigation effect
    • Y02T10/70—Energy storage systems for electromobility, e.g. batteries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/60—Other road transportation technologies with climate change mitigation effect
    • Y02T10/7072—Electromobility specific charging systems or methods for batteries, ultracapacitors, supercapacitors or double-layer capacitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T90/00—Enabling technologies or technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02T90/10—Technologies relating to charging of electric vehicles
    • Y02T90/16—Information or communication technologies improving the operation of electric vehicles

Definitions

  • the technical background of this invention is concerned with pharmaceutical industry by mixing natural ingredients.
  • AIDS is a universal problem. In 2002, 60 million people were infected with HIV, as a result of which unfortunately almost 20 million people passed away. Currently, over 42 million people suffer from AIDS. HIV victims require a long term treatment period. At the present time, the available treatment pattern includes curing not only the viruses but also infections.
  • the most preferable drugs used for treating the infections derived from Retroviruses are Anti-virus drugs especially for HIV.
  • the anti-virus drugs used for HIV treatment generally belong to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIS), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS), Protease inhibitors (Pis).
  • the present invention is concerned with an herbal anti-virus mixture which contributes to the process of preparing an edible antiviral intravenous compound composed of the leaf and root of cranesbill, basil, mint, date and the enzyme generated in the stomach of mosquito which is helpful for treating HIV or AIDS.
  • cranesbill leaf and root, mint, basil and date are boiled in the distilled water.
  • this mixture is purified and segregated by filter. This process needs to be repeated for 4 times and distillation is done while the solution is at the boiling point. Please be informed that the heat needs to be mild and we should prevent sudden temperature.
  • the solution needs to stay stable for 30 minutes so that the herbal material can sediment and five drops of the enzyme generated in the mosquito's stomach is mixed with the solution, heated within 45 degrees in the magnet heater and without temperature fluctuations for 25 minutes and beaten with the automatic electric mixer so that the mixture can be homogeneous.
  • the solution is refined by a high speed centrifuge and heated to gain the final compound which destroys surface antigens and HIV genome by attacking the virus and killing HIV, so it plays a major role in treating AIDS and HIV related to immune deficiency syndrome ⁇
  • the other aspect of the present invention is that this compound has antivirus, antibacterial, antioxidant, immunity motivator, anticancer, Adaptogens, genotoxic effects, radio protection (protection against lipid peroxidation, DNA damage), liver protection, heart protection, anti-pain, anti-vomiting, anti-spasm, anti-ulcer, anti-spermatogenesis, anti-proliferative, improving effects, reducing Lipid peroxidation, activating anti-oxidant enzymes, activating anti-oxidant recovery enzymes GSH (Glutathione), activating the defense system and keeping it stable, Apoptosis , anti-stress effects, anti-Hyperlipidemia and stable membrane. Extermination and termination quality of herbal compound as well as mosquito enzyme was tested inside the body in the laboratory.
  • This compound is distributed widely in the tissues and body liquid.
  • This test shows that the herbal medicine which is made of cranesbill root and leaf, mint, basil, date and their mixture with the enzyme that is taken from the mosquito's stomach is able to fight against the virus and stop their activity and destroy infection.
  • the surface antigens of AIDS virus including GP 36, GP 160 and GP 41 in a volunteer AIDS victim was stopped after taking this drug.
  • the results of this test show that the fever vanished, his appetite increased, the general weakness improved and his/her weight changed from 46 kgs to its normal weight that is 61 kgs and the person returned back to his/her normal state.
  • the reported side effects include ague followed by atopic type 1 and the probable growth of allergic reactions such as asthma.
  • Anti-virus herbal compound as well as the enzyme derived from mosquito discharge removes 99 percent of infection and virus out of 100% of the HIV that is available in the blood and body. This shows a dramatic decrease in the disease spread, a growth in AIDS virus treatment and the infectious part. The present results can change based on the difference in the defense system of different people and the treatment period is not stable for the different immune systems. Other factors include the kind of HIV, the number of virus from which the infection is caused and signifies the stage of disease affects the time of treatment. The leaf and root of the cranesbill is effective for increasing body immune system and preventing virus replication and infection. The ingredient of mint removes most of the symptoms that are related to AIDS in the human body.
  • This medicine is able to be taken by all of the people suffering from type 1 and 2 of AIDS (either virus or infection). Generally, it is applicable in medical and pharmaceutical industry and it can be used for preventing or treating the virus or infection caused by AIDS.
  • Pregnant women, children, infants and even those who suffer from asthma can take this medicine with the consultation and prescription of their doctors but its dose must be determined based on their condition.
  • the density and number of the dose may be different owing to the intensity of infections related to AIDS.
  • Preparing pharmaceutical composition and relaxing material might be divided in equal dose during 12 hours. After an intradermal test, the initial dose at the rate of 1 ml is used either abdominally or orally.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Power Engineering (AREA)
  • Virology (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Sustainable Development (AREA)
  • Sustainable Energy (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un mélange anti-virus à base de plantes contribuant au procédé de préparation d'un composé intraveineux antiviral comestible composé de la feuille et de la racine du géranium, du basilic, de la menthe, de la date et de l'enzyme produite dans l'estomac du moustique qui est utile pour le traitement du VIH ou du SIDA. Tout d'abord, la feuille et la racine du géranium, du basilic, de la menthe et de la date sont bouillies dans de l'eau distillée. Ensuite, ce mélange est purifié et séparé par filtrage. L'autre aspect de la présente invention est que ce composé présente des effets antiviraux, antibactériens, antioxydants, activateurs de l'immunité, anticancéreux, adaptogènes, génotoxiques, des effets de radioprotection (protection contre la peroxydation lipidique, la lésion d'ADN), de protection du foie, de protection du cœur, antidouleurs, anti-vomissements, anti-spasme, anti-ulcères, anti-spermatogenèse, antiprolifératifs, des effets d'amélioration, réduisant la peroxydation lipidique, activant les enzymes antioxydantes, activant les enzymes GSH (glutathione) de récupération antioxidantes, activant le système de défense et maintenant sa stabilité, d'apoptose, des effets anti-stress, anti-hyperlipidémie et une membrane stable.
PCT/IB2015/052367 2015-03-29 2015-03-31 Procédé de fabrication d'un médicament à base de plantes au moyen d'une enzyme de l'estomac du moustique pour le traitement de virus et du sida Ceased WO2016156920A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IR13943000105 2015-03-29
IR139450140003000105 2015-03-29

Publications (1)

Publication Number Publication Date
WO2016156920A1 true WO2016156920A1 (fr) 2016-10-06

Family

ID=83280643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/052367 Ceased WO2016156920A1 (fr) 2015-03-29 2015-03-31 Procédé de fabrication d'un médicament à base de plantes au moyen d'une enzyme de l'estomac du moustique pour le traitement de virus et du sida

Country Status (1)

Country Link
WO (1) WO2016156920A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108210540A (zh) * 2016-12-12 2018-06-29 中国疾病预防控制中心辐射防护与核安全医学所 红花水提取物在制备抗辐射药物中的应用
CN110478382A (zh) * 2019-09-29 2019-11-22 中国科学院寒区旱区环境与工程研究所 沙米总黄酮的提取工艺、提取物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101869579A (zh) * 2009-04-23 2010-10-27 罗家弃 艾滋病毒溶解酶
WO2012176215A1 (fr) * 2011-06-20 2012-12-27 Pundaleekappa Shinhasan Manohar Composition antivirale à base de plantes pour le traitement du vih et du syndrome d'immunodéficience acquise associé au vih

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101869579A (zh) * 2009-04-23 2010-10-27 罗家弃 艾滋病毒溶解酶
WO2012176215A1 (fr) * 2011-06-20 2012-12-27 Pundaleekappa Shinhasan Manohar Composition antivirale à base de plantes pour le traitement du vih et du syndrome d'immunodéficience acquise associé au vih

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 2000 (2000-01-01), MLINARIC A ET AL: "Screening of selected plant extracts for in vitro inhibitory activity on HIV-1 reverse transcriptase (HIV-1 RT).", XP002744236, Database accession no. NLM10683878 *
MLINARIC A ET AL: "Screening of selected plant extracts for in vitro inhibitory activity on HIV-1 reverse transcriptase (HIV-1 RT).", DIE PHARMAZIE JAN 2000, vol. 55, no. 1, January 2000 (2000-01-01), pages 75 - 77, ISSN: 0031-7144 *
SERKEDJIEVA J: "Antiinfective activity of a plant preparation from Geranium sanguineum L", PHARMAZIE, vol. 52, no. 10, 1997, pages 799 - 802, XP001526580, ISSN: 0031-7144 *
YAMASAKI KATSUHIRO ET AL: "Anti-HIV-1 activity of herbs in Labiatae", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), vol. 21, no. 8, 1 August 1998 (1998-08-01), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, pages 829 - 833, XP009110507, ISSN: 0918-6158 *
YANG Y C ET AL: "Optimisation of microwave-assisted enzymatic extraction of corilagin and geraniin from Geranium sibiricum Linne and evaluation of antioxidant activity", FOOD CHEMISTRY, vol. 122, no. 1, 1 September 2010 (2010-09-01), ELSEVIER LTD, NL, pages 373 - 380, XP026997566, ISSN: 0308-8146, [retrieved on 20100301] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108210540A (zh) * 2016-12-12 2018-06-29 中国疾病预防控制中心辐射防护与核安全医学所 红花水提取物在制备抗辐射药物中的应用
CN110478382A (zh) * 2019-09-29 2019-11-22 中国科学院寒区旱区环境与工程研究所 沙米总黄酮的提取工艺、提取物和应用

Similar Documents

Publication Publication Date Title
CA1326450C (fr) Modulation des manifestations associees au virus du sida au moyen d'arn a double brin
JPH02111725A (ja) 医薬組成物
US5063209A (en) Modulation of aids virus-related events by double-stranded RNAs
Mehandru et al. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection
WO2016156920A1 (fr) Procédé de fabrication d'un médicament à base de plantes au moyen d'une enzyme de l'estomac du moustique pour le traitement de virus et du sida
CN110638871A (zh) 一种抗蜜蜂麻痹病毒提取物及其制备方法
Andrew et al. Histologic effect of garlic extract on the spleen of adult wistar rat
CN119318724A (zh) 一种负载抑炎因子的重组减毒柯萨奇b3病毒在制备用于治疗外伤性颅脑损伤的药物中的应用
JP4121957B2 (ja) 藍調製物、ならびにそのヒト免疫不全ウイルスの感染予防または治療における用途
CN105233250B (zh) 一种用于治疗脑病的复合生物制剂
CN108310266B (zh) 一种治疗病毒疣的中药
KR101426996B1 (ko) 테트라케라 스캔덴스 에탄올 추출물을 유효성분으로 포함하는 항바이러스 조성물 및 이의 용도
CN107320471B (zh) 一种治疗结核病的环丝氨酸药物组合物及其应用
CN110384718A (zh) 一种抗肿瘤免疫检查点阻断剂
KR20160023238A (ko) 청고추 추출물을 유효 성분으로 포함하는 인플라마좀 매개 염증성 질환 및 인플루엔자 바이러스 감염 예방, 개선용 조성물
Iqbal et al. Alternative treatment in Hepatitis B by using polyherbal formulation.
CN105106236A (zh) 一种治疗带状泡疹的外用擦剂及其制备方法
JP5561647B2 (ja) 生体防御機能因子の発現亢進剤
CN108409839A (zh) 一种MDM2与p53相互作用的多肽抑制剂及其应用
RU2755638C2 (ru) Способ повышения противоопухолевой резистентности, антиоксидантного и иммуностимулирующего воздействия на организм
KR101637472B1 (ko) 마늘 추출물을 유효 성분으로 포함하는 인플라마좀 매개 염증성 질환 예방 및 치료용 조성물
RU2281113C1 (ru) Средство для лечения гепатитов, токсоплазмоза, цитомегаловирусной инфекции и гриппа
CN110536690B (zh) 用于预防或治疗丙型肝炎病毒感染疾病的药学组合物
CN104623420B (zh) 一种治疗扁平疣的中药软膏
JP5651834B2 (ja) 赤血球凝集阻害剤、および赤血球の凝集阻害方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15716588

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13.02.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 15716588

Country of ref document: EP

Kind code of ref document: A1